
Marker Therapeutics Experiences Revision in Its Stock Evaluation Amid Financial Challenges
2025-11-20 15:40:01Marker Therapeutics, Inc. reported a challenging quarter ending June 2025, with significant declines in net sales and critical financial metrics. Despite achieving its highest operating cash flow, the company struggles with low net sales and negative returns, contrasting sharply with broader market performance.
Read full news articleNo announcement available
Corporate Actions
No corporate action available






